Democritus University of Thrace (DUTH)
Η συμβολή της διεγχειρητικής υπερθερμικής έγχυσης χημειοθεραπευτικών φαρμάκων υπό τη μορφή της συνεχούς έκπλυσης της περιτοναϊκής κοιλότητας στην αντιμετώπιση της καρκινωμάτωσης του περιτόναιου
Abstract
dc:descriptionPeritoneal carcinomatosis from intraperitoneal solid tumors carries a fatal prognosis. Surgical removal of peritoneal carcinomatosis (PC) is not only difficult but almost impossible and the use of systemic chemotherapy has not been shown to be effective in the management of PC. The feasibility and effectiveness of intraperitoneal instillation of chemotherapeutic agents, with its direct cytotoxic effect on peritoneal neoplasmatic nodules has been proven in a large number of Phase I and II studies. Continuous Intraoperative Intraperitoneal Hyperthermic Chemoperfusion (CIIPHCP) has been used successfully in the treatment of some low-potential malignancies, such as pseudomyxoma peritonei, but even in epithelial ovarian neoplasms with intraperitoneal spread, as well as in patients with PC of gastrointestinal origin. The purpose of the present study was the evaluation of CIIPHCP in the treatment of advanced gastric adenocarcinoma with peritoneal spread and -mainly- in the treatment of primary and recurrent epithelial ovarian cancer. a) 24 non-randomized patients have been treated for advanced primary or recurrent gastric adenocarcinoma with peritoneal spread with CIIPHCP. From those patients, only seven were subjected to therapeutic resection of the tumor and were studied extensively. The disease of the six patients who were primarily diagnosed and underwent gastrectomy was adenocarcinoma Stage IIIA-IV with advanced tumor growth penetrating the serosa (T3-T4). One more female patient was treated for local recurrence at the gastric stump and simultaneous Kruckenberg disease with malignant ascites. Those seven patients underwent therapeutic gastrectomy, D2-lymphadenectomy without splenectomy, omentectomy and removal of large intraperitoneal neoplasmatic nodules. In one female patient, resection of both ovaries was performed. After all surgical dissections and anastomoses had been made, all patients underwent CIIPHCP. The seven patients submitted to therapeutic resection of the neoplasm, received regional intra-arterial chemotherapy with the FAM regimen. After completion of the three cycles of intra-arterial chemotherapy, all seven patients received systemic intravenous chemotherapy. The median survival time of those seven patients was 29.5 months and the median progression free survival time was 15 months, while only one patient died with local recurrence at the gastric stump. b) Regarding the primary epithelial ovarian cancer, 27 patients have been treated with a combination of cytoreductive surgery and CIIPHCP. Median survival for 18 patients with residual disease less than 1.5 cm was 42.0 months, whereas for the nine patients with residual disease equal or greater than 1.5 cm, the median survival was 10.0 months. This difference was statistically very significant (p=0.0023). Five patients (18.5%) are still alive, 90, 78, 75, 54 and 38 months, respectively, after CIIPHCP. The neoplasmatic ascites disappeared postoperatively and median ascites-free period after the operation was 22 months. 20 more, heavily pre-treated patients (with surgery and systemic chemotherapy) with recurrent epithelial ovarian cancer, have been treated with a combination of cytoreductive surgery and CIIPHCP. In 14 out of the 20 pts (70%) the recurrence occurred during chemotherapy or within 6 months after the end of the chemotherapy. Median survival time for patients with residual disease less than 1.5 cm was 29.0 months, with four patients still alive 110, 109, 51 and 37 months, respectively, after CIIPHCP, whereas for patients with residual disease equal or greater than 1.5 cm, the median survival time was 7.0 months. This difference was statistically significant (p < 0.05). Thirteen pts (65%) had preoperatively malignant ascites, whereas the remaining seven pts (35%) had positive peritoneal cytology washings. The ascites disappeared in all of the 13 pts with preoperative ascites. Median ascites-free period after CIIPHCP was 21 months. Although not measured at the time of this study, quality of life showed an interesting improvement after operation and CIIPHCP, with 16 out of the 20 patients (80%) having a Karnofsky-index of 90% just before the beginning of postoperative IV chemotherapy and chemotherapy was better tolerated. In conclusion, the survival data and the disappearance of the malignant ascites postoperatively in combination with the limited morbidity, suggest that Continuous Intraoperative Intraperitoneal Hyperthermic Chemoperfusion (CIIPHCP) is an effective treatment option for patients with neoplasms confined in the peritoneal cavity for relatively long time. One should single out the efficacy of the method especially in the treatment of primary epithelial ovarian cancer and its recurrences.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2004
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chatzigeorgiou, Konstantinos
- Χατζηγεωργίου, Κωνσταντίνος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/17350